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ABS TRACT
Background and objectives: Alzheimer’s disease (AD) shares certain etiological features with
autoimmunity. Prevalence of autoimmunity varies between populations in accordance with variation
in environmental microbial diversity. Exposure to microorganisms may improve individuals’
immunoregulation in ways that protect against autoimmunity, and we suggest that this may also be
the case for AD. Here, we investigate whether differences in microbial diversity can explain patterns of
age-adjusted AD rates between countries.
Methodology: We use regression models to test whether pathogen prevalence, as a proxy for microbial
diversity, across 192 countries can explain a significant amount of the variation in age-standardized AD
disability-adjusted life-year (DALY) rates. We also review and assess the relationship between pathogen
prevalence and AD rates in different world populations.
Results: Based on our analyses, it appears that hygiene is positively associated with AD risk. Countries
with greater degree of sanitation and lower degree of pathogen prevalence have higher age-adjusted AD
DALY rates. Countries with greater degree of urbanization and wealth exhibit higher age-adjusted AD
DALY rates.
Conclusions and implications: Variation in hygiene may partly explain global patterns in AD rates.
Microorganism exposure may be inversely related to AD risk. These results may help predict AD burden
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in developing countries where microbial diversity is rapidly diminishing. Epidemiological forecasting is
important for preparing for future healthcare needs and research prioritization.
KEYWORDS : Alzheimer’s disease; hygiene hypothesis; inflammation; dementia; pathogen preva-
lence; Darwinian medicine
INTRODUCTION
Exposure to microorganisms is critical for the
regulation of the immune system. The immunodys-
regulation of autoimmunity has been associated
with insufficient microorganism exposure [1].
Global incidence patterns of autoimmune diseases
reflect this aspect of their etiology: autoimmunity
is inversely correlated to microbial diversity [1, 2].
The inflammation characteristic of Alzheimer’s
disease (AD) shares important similarities with
autoimmunity [3, 4]. The similarity in immuno-
biology may lead to similarity in epidemiological pat-
terns. For this reason, here we test the hypothesis
that AD incidence may be positively correlated
to hygiene. The possibility that AD incidence is
related to environmental sanitation was previously
introduced by other authors [5, 6], and remains as of
yet untested.
The ‘hygiene hypothesis’ [7] suggests that certain
aspects of modern life (e.g. antibiotics, sanitation,
clean drinking-water, paved roads) are associated
with lower rates of exposure to microorganisms
such as commensal microbiota, environmental
saprophytes and helminths than would have been
omnipresent during the majority of human history
[8]. Low amount of microbe exposure leads to low
lymphocyte turnover in the developing immune sys-
tem, which can lead to immunodysregulation.
Epidemiological studies have found that popula-
tions exposed to higher levels of microbial diversity
exhibit lower rates of autoimmunities as well as
atopies [9], a pattern that holds for countries
with differing degrees of development [10, 11].
Differences in environmental sanitation can partly
explain the patterns of autoimmunity and atopy
across history and across world regions [2, 12].
Patient-based studies have demonstrated that indi-
viduals whose early-life circumstances were
characterized by less exposure to benign infectious
agents exhibit higher rates of autoimmune and
atopic disorders. This pattern has been
demonstrated for farm living versus rural non-farm
living [13–15], daycare attendance [16, 17], more
siblings [7, 18], later birth order [19–21] and pets
in the household [22], exhibiting lower rates of
atopic and autoimmune disorders.
Low-level persistent stimulation of the immune
system leads naı¨ve T-cells to take on a suppressive
regulatory phenotype [23] necessary for regulation of
both type-1 inflammation (e.g. autoimmunity) and
type-2 inflammation (e.g. atopy) [12, 24, 25].
Individuals with insufficient immune stimulation
may experience insufficient proliferation of regula-
tory T-cells (TRegs) [26, 27]. AD has been described
as a disease of systemic inflammation [28], with the
AD brain and periphery exhibiting upregulated type-
1 dominant inflammation [29]: a possible sign of
TReg deficiency. Immunodysregulation as a conse-
quence of low immune stimulation may contribute
to AD risk through the T-cell system. Altogether, we
suggest that a hygiene hypothesis for Alzheimer’s
disease (HHAD) predicts that AD incidence may
be positively correlated to hygiene.
The period from gestation through childhood is
typically thought to be a critical window of time dur-
ing which the immune system is established [14, 30,
31], with some authors limiting this critical window
to the first 2 years of life [32]. However, proliferation
of TRegs occurs throughout the life course: there are
age-related increases in number of TRegs [30, 33] with
peaks at adolescence and in the sixth decade [34].
Therefore, it may be not only early-life immune
stimulation that affects AD risk (and perhaps
risk of other types of immunodysregulation) but also
immune stimulation throughout life. Our study is
designed based on the hypothesis that microorgan-
ism exposure across the lifespan may be related
to AD risk.
At an epidemiological level, our prediction is
opposite to Finch’s [6] hypothesis that early-life
pathogen exposure should be positively correlated
to AD risk. Both their and our predictions are based
on speculation about T-cell differentiation, although
we reached opposite suppositions. It is clear
that inflammation is upregulated in AD, and Finch
suggested that pathogen exposure, which is pro-
inflammatory, may increase AD risk [6]. We propose
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that at the population level, pathogen exposure,
as a proxy for benign microorganism exposure,
may be protective against AD.
Griffin and Mrak [5] suggested that an HHAD
is justified because hygiene-related changes in
immune development are probably related to AD
etiology, but it is not possible to predict the direc-
tionality of this effect. They focus on how hygiene
might influence microglial activation and IL-1
expression, and the opposing effects these changes
may have on AD-relevant pathways.
Our prediction, Finch’s contrary [35] prediction,
and the assertion of Griffin and Mrak that further
research is needed to establish the directionality
of hygiene’s effect on AD motivated this empirical
investigation of whether pathogen prevalence was
correlated to AD rates at the country level. This
information could lead to a better understanding
of the environmental influences on AD etiology
and could help judge the accuracy of existing predic-
tions for future AD burden.
METHODS
In order to test whether there is epidemiological evi-
dence for an HHAD, data for a wide range of
countries were compared. Age-standardized disabil-
ity-adjusted life-year (DALY) rates (henceforth ‘AD
rates’) in 2004 were evaluated in light of proxies for
microbial diversity across a range of years selected
to fully encompass lifespans of individuals in the
AD-risk age group in 2004.
Prevalence of Alzheimer’s and other dementias
We utilized the WHO’s Global Burden of Disease
(GBD) report published in 2009, which presents
data for 2004 [36]. The WHO only reports informa-
tion for AD and other dementias across different
countries, rather than AD alone. This variable does
not include Parkinsonism [37]. While there are other
types of dementia, AD accounts for between 60%
and 80% of all dementia cases [38], and the
neurobiological distinctions between some of the
subtypes may be vague [39, 40]. The WHO report
presents three variables related to AD: age-
standardized DALY, age-standardized deaths, and
DALY for age 60+. There is low correlation between
these three measures (linear regressions after ne-
cessary data transformations had R-squared values
0.040; 0.089; 0.041).
The WHO’s GBD report includes the following
ICD-10 codes as ‘Alzheimer’s and other dementias:’
F01, F03, G30–G31, uses an incidence-based ap-
proach, 3% time discounting, the West Level 26
and 25 life tables for all countries assuming global
standard life expectancy at birth [41], standard GBD
disability weights [42] and non-uniform age-weights
[43, 44]. DALYs are calculated from years of lost life
(YLL) and years lost due to disability (YLD). YLL data
sources for AD included death registration records
for 112 countries, population-based epidemiological
studies, disease registers and notification systems
[45]. Vital registration data with coverage over 85%
were available for 76 countries, and information for
the remaining 114 countries was calculated using a
combination of cause-of-death modeling, regional
patterns and cause-specific estimates (see [45] for
details). YLD data sources for AD included disease
registers, population surveys and existing epidemio-
logical studies [43]. When only prevalence data were
available, incidence statistics were modeled from
estimates of prevalence, remission, fatality and
background mortality using the WHO’s DisMod II
software [43].
Age-standardized rates were calculated by
adjusting the crude AD DALY for 5-year age groups
by age-weights reflecting the age-distribution of the
standard population [35]. The new WHO World
Standard was developed in 2000 to best reflect
projections of world age-structures for the period
2000–25 [35], and particularly closely reflects the
population age-structures of low- and middle-
income countries [46].
DALYs as better measure than death rates.
AD as cause of death is a particularly flawed meas-
urement across different countries, as certain
countries rarely attribute mortality to AD or recog-
nize dementia as abnormal aging [47], and other
causes of death may occur at far greater frequencies
masking AD prevalence. The DALY measurement is
the sum of years lost due to premature mortality and
years spent in disability. The number of years lost
due to premature mortality is based on the standard
life expectancy at the age when death due to AD
occurs [48]. Therefore, this measurement omits the
effects of differential mortality rates previous to
age 65, which accounts for the vast majority of dif-
ferences in life expectancy between developed and
developing countries [49], opportunely isolating the
effects of later life mortality causes. Therefore, DALY
includes but is not limited to AD as official cause of
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death, making it a more inclusive variable than AD
as cause of death.
Age-standardized data better indicator than
age 60+ data.
Age-standardized rates represent what the burden
of AD would be if all countries had the same age-
distribution [35]. While the WHO GBD report
also provides DALY for ages 60+, these data are
not age-standardized. Using DALY for ages 60+, a
country with a significant population over age 85,
for instance, would always appear to have greater
AD incidence than a country with few people over
85, regardless of differences in age-specific AD
incidence in the two countries. This is due to the
exponential way in which AD risk increases with
age [50, 51]. Differences in age-specific AD incidence
would be masked by differences in population
age structure. See Supplementary Section S6 for
examples and further explanation.
Predictive variables
The hygiene hypothesis is sometimes referred to as
the ‘old friends hypothesis’ [52]. This alternative title
highlights the fact that for the vast majority of our
species’ history, humans would have been regularly
exposed to a high degree of microbial diversity,
and the human immune system was shaped through
natural selection in these circumstances [53]. With
rapidly increasing global urbanization beginning
in the early nineteenth century, individuals began
to experience diminishing exposure to these
‘friendly’ microbes due to diminishing contact with
animals, feces and soil [1]. The microbes that were
our ‘old friends’ previous to this epidemiological
transition whose absence may lead to immunodys-
regulation in modern environments included gut,
skin, lung and oral microbiota; orofecally trans-
mitted bacteria, viruses and protozoa; helminthes;
environmental saprophytes; and ectoparasites
[1, 52]. The predictive variables in our analysis were
selected for their relevance to these ‘old friends’.
These variables do not specifically reflect exposure
to those microbiota and commensal microorgan-
isms that were omnipresent during our evolutionary
history, but rather cover a more general collection
of microbial exposures. This inclusive approach is
both because of limitations of available datasets,
and because it is not known if particular microbial
elements specifically relate to AD etiology.
Murray and Schaller [54] assessed historical dis-
ease prevalence for the years 1944–61. Their ‘seven-
item index of historical disease prevalence’ included
leishmanias, schistosomes, trypanosomes, malaria,
typhus, filariae and dengue. Their ‘nine-item index’
included the above diseases plus leprosy and a con-
temporary measure of tuberculosis. Another meas-
ure of pathogen exposure [55] combines data from
the WHO and the ‘Global Infectious Diseases and
Epidemiology Network’ (GIDEON) for 2002 and
2009. The WHO reports countries’ ‘percent popula-
tion using improved sanitation facilities’, which
‘separate human excreta from human contact’ [56],
and ‘improved drinking-water sources’, which pro-
tect the source from contamination [56]. Of 3 years
for which sufficient data were available, we chose to
look at 1995 (Supplementary Section S1). ‘Infant
mortality rate’ (IMR) is measured as number of in-
fant mortalities per 1000 live births [57]. We con-
sulted historical IMR statistics [58] for years 1900–
2002. The World Bank reports countries’ ‘gross na-
tional income’ (GNI) per capita at purchasing power
parity (PPP) [57], the economic variable that contrib-
utes to the composite Human Development Index
and is therefore an indicator of the contribution of
wealth to quality of life. We looked at both the earliest
year with sufficient data available, 1970 and 2004.
‘Gross domestic product’ (GDP) per capita (PPP)
is an economic measure of a country divided by its
mid-year population [57], often used as a measure of
standard of living, although it is not a direct assess-
ment of this. We consulted Maddison’s historical
economic statistics [59] for GDP from 1900 to
2002. Children growing up in rural areas may be
more exposed to pathogens due to factors including
unpaved roads, contact with livestock and animal
feed, and consumption of unprocessed milk [13,
14]. The World Bank reports the ‘percent of a coun-
try’s population living in urban areas’ [57], and we
looked at both the earliest year with data available,
1960 and 2004.
Statistical methods
All variables were transformed to optimize distri-
bution symmetry to avoid undue influence by
countries with extreme values for each variable
(Supplementary Section S1). Linear regression was
used to determine whether there was a relationship
between each of the microbial exposure proxies and
AD rate between countries. As there was reason to
suspect predictive overlap among the variables, a
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principal component regression was conducted
(Supplementary Section S4).
To explore which part of the lifespan has the most
bearing on AD, we measure the strength of the same
proxy across several years as a predictor of 2004 AD
prevalence. We compare historical and contempor-
ary disease prevalence, and GNI and urban living.
Also, two of the proxies had more detailed historical
information available: GDP [59] and IMR [58]. GDPs
and IMRs from years spanning 1900–2002 were
compared. Each year’s GDP and IMR were
compared to 2004 AD rates by linear regression.
The resulting regression coefficients were inter-
preted as the degree to which each year’s GDP or
IMR and 2004 AD were correlated (Supplementary
Section S5).
RESULTS
Statistical analyses revealed highly significant
relationships between various measures of hygiene
and age-adjusted AD DALY. High levels of pathogen
exposure were associated with lower AD rates.
Countries with higher disease and pathogen preva-
lence and IMR had lower 2004 AD rates (Table 1,
Figs 1–4, Fig. S1). These results are consistent with
a protective role of exposure to microbial diversity
against AD, and support an HHAD.
Greater degree of hygiene, and therefore poten-
tially lower degree of microorganism exposure, was
associated with higher AD rates. Countries with
a higher percent of the population using improved
sanitation facilities, improved drinking-water
sources, living in urbanized areas, higher GNI and
GDP per capita (PPP) had higher rates of AD in 2004
(Table 1, Fig. 3, Figs S2–S5). The existence of a
strong positive correlation between historical levels
of sanitation and AD rate in 2004 is consistent with
the predictions of the HHAD.
Comparing predictive power of data from
different years
Our results indicate that microbe exposure across
the lifespan, not necessarily just during early-life,
is associated with AD burden. Predictive variables
reflecting the years during which elderly people in
2004 would have experienced their earlier years of
life were not consistently better indicators of 2004
AD rate compared to years during which they would
have spent their mid or later life years, consistent
with observations of lifelong TReg proliferation
[30, 33, 34]. Contemporary measures were more
powerful indicators in the cases of contemporary
parasite stress versus historical disease prevalence,
and GNI in 2004 versus 1970, while percent of
population living in urban areas in 1960 versus
2004 was a slightly better indicator of AD in 2004
(Fig. 3).
A series of linear regressions measuring the rela-
tionship between IMRs from 1900 to 2002 and AD
in 2004 revealed that IMR was significantly
Table 1. An evaluation of proxies for hygiene as predictors of Alzheimer burden
Variable Year N R2 P Direction
consistent
with HHAD?
Historical disease prevalence nine-item 1944–61 148 0.358 **** Yes
Historical disease prevalence seven-item 1944–61 191 0.242 **** Yes
Contemporary parasite stress 2002, 2009 190 0.373 **** Yes
Improved sanitation facilities 1995 177 0.334 **** Yes
Improved drinking-water sources 1995 178 0.327 **** Yes
GNI 1970 171 0.296 **** Yes
2004 174 0.328 **** Yes
Urban % 1960 187 0.282 **** Yes
2004 187 0.204 **** Yes
Linear regression for each predictive variable after transformation to optimize symmetry (Supplementary Section S1).
Principal component regression for parasite stress, sanitation facilities, drinking-water sources, infant mortality,
GNI and urbanization had a higher R2 than any predictive variable on its own (Supplementary Section S4).
****P< 0.0000.
Hygiene and Alzheimer’s epidemiology Fox et al. | 177
negatively correlated to 2004 AD rates with an
increasing annual ability to explain variance
(Fig. 4, Supplementary Section S5). This analysis
was restricted to countries with IMR data across
1900–2002 (N = 45) and thus was free from sample
size biases.
Similarly, a series of linear regressions measuring
the relationship between GDPs from 1900 to 2002
and AD in 2004 revealed that GDP was significantly
positively correlated to 2004 AD rates, although the
increasing annual ability to explain variance was only
consistently true for years 1940–2002 (Fig. S7).
Principal component analysis
A principal component regression analysis
demonstrated that the combined statistical impact
of the proxies for microbial diversity had a
significant effect on AD rates. There were high de-
grees of correlation between disease prevalence,
parasite stress, sanitation facilities, improved
drinking water, GNI and urban population
(Table S1). There was a significant relationship be-
tween the principal component and 2004 AD rate
(N = 159, R2 = 0.425, P< 0.0000) (Supplementary
Section S4, Fig. S6).
DISCUSSION
Inflammation plays an important role in AD patho-
genesis, and previous authors have hypothesized
that immune stimulation could increase AD risk
through T-cell [6] or microglial action [5, 60].
However, our results indicate that some immune
Figure 1. Countries’ parasite stress negatively correlated to Alzheimer’s burden
Countries with higher contemporary parasite prevalence have lower age-standardized rates of Alzheimer’s in 2004. N= 190,
R2 = 0.373, P< 0.0000. Contemporary parasite stress [55] combines years 2002 and 2009, and the variable is transformed by
adding a constant and taking square root. The Alzheimer variable is transformed by adding a constant and taking the natural log
of 2004 Alzheimer age-standardized DALY [36]
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stimulation may protect against AD risk. The trad-
itional hygiene hypothesis has effectively explained
prevalence rates of autoimmunity and atopy in
many populations. We have found that the hygiene
hypothesis can help explain some patterns in rates
of AD, as predicted previously [5, 8] with a direction
of correlation consistent with our predictions based
on T-cell differentiation.
In support of the HHAD, we found that proxies
for immune stimulation correlated to AD rates
across countries. These proxies included historical
disease prevalence, parasite stress, access to sani-
tation facilities, access to improved drinking-water
sources, IMR, GNI, GDP and urbanization. These
variables’ relationships to AD rate are independent
of countries’ age structures.
Further evidence supporting this hypothesis
from previous studies includes higher incidence of
AD in developed compared to developing countries,
comparison to incidence patterns of other disorders
with similar immunobiology and consideration of
the etiology of inflammation in AD.
Higher Alzheimer’s risk in industrialized
countries and urban environments
People living in developed compared to developing
countries have higher rates of AD. AD incidence at
age 80 is higher in North America and Europe than
in other countries [51]. A meta-analysis found
that dementia incidence doubled every 5.8 years in
high income countries and every 6.7 years in low-
and middle-income countries, where the overall
incidence of dementia was 36% lower [39] (but
see [61]). Another meta-analysis found that age-
standardized AD prevalences in Latin America,
China and India were all lower than in Europe,
and within those regions, lower in rural compared
to urban settings [62]. In a meta-analysis of
Asian countries, the wealthier ones had higher
Figure 2. Countries’ historical disease prevalence negatively correlated to Alzheimer’s burden 2004
Countries with historically more infectious disease have lower age-standardized rates of Alzheimer’s in 2004.N= 148, R2 = 0.358,
P< 0.0000. Historical disease prevalence 9-item data compiled by Murray and Schaller for years 1944–61 [54]. Alzheimer preva-
lence variable is transformed by adding a constant and taking the natural log of 2004 Alzheimer age-standardized DALY [36]
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age-standardized rates of AD prevalence than
the poorer countries [63]. A meta-analysis of
rural versus urban AD incidence demonstrated
that, overall, rural living was associated with higher
incidence, but when only high-quality studies were
considered, rural living was associated with reduced
incidence [47].
In developing countries and rural environments,
there are higher rates of microbial diversity,
exposure and infection. It is well-documented
that rates of atopies including allergies, hay fever,
eczema and asthma are lower in developing than
developed countries [12, 64], as are autoimmunities
such as multiple sclerosis, type-1 diabetes mellitus
and Crohn’s disease [65], and the same pattern
holds for rural versus urban environments [2, 14,
15] (but see [66]). We found that wealthier countries
(Figs S3 and S4) and more urbanized countries
(Fig. 2) had greater AD rates after adjustment for
population age-structures.
Alzheimer’s risk changes with environment
Previous studies have found that individuals from
similar ethnic backgrounds living in low versus high
sanitation environments exhibit low versus high risk
of AD. African Americans in Indiana had higher age-
specific mortality-adjusted incidence rates of AD
than Yoruba in Nigeria [67], and while there is no
indication that the sampled African Americans had
any Yoruba or even Nigerian heritage, the results
are at least consistent with our predictions for the
HHAD. There is also evidence that immigrant popu-
lations exhibit AD rates intermediate between their
home country and adopted country [63, 68–70].
Moving from a high-sanitation country to a
Figure 3. Countries’ urbanization 1960 positively correlated to Alzheimer’s burden 2004
Countries with more of the population living in urban areas in 1960 have higher age-standardized rates of Alzheimer’s in 2004.
N= 187, R2 = 0.282, P< 0.0000. Urbanization data [57] are transformed by adding a constant and taking the square root. The
Alzheimer prevalence variable is transformed by adding a constant and taking the natural log of 2004 Alzheimer age-standardized
DALY [36]
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low-sanitation country can decrease immigrants’ AD
risk [47] [e.g. Italy to Argentina [71] (but see [72])].
Our results are consistent with the possibility that
living in different countries confers different AD risk,
stratified by sanitation (Figs 1 and 2).
Alzheimer’s risk and family size
Having relatively more siblings would be expected
to correspond to higher rates of early-life immune
activation because of more interaction with
other children who may harbor ‘friendly’ commensal
microorganisms. Individuals with more siblings
have lower atopy prevalence [7, 18, 20]. Certain
studies have found that individuals with AD have
fewer siblings than controls [73, 74], but Moceri
and coworkers found no difference [75], and the
opposite [76].
Younger siblings compared to first-borns would
be expected to have higher rates of microorganism
exposure because this would indicate higher propor-
tion of childhood spent in contact with siblings.
Later-born siblings have lower rates of atopy [7, 20,
66, 77, 78]. No birth order effect has been observed
for AD [79].
Lymphocytes and Alzheimer’s
T cells are important modulators of immune func-
tion and have been identified as the major affected
system in trends attributable to the hygiene hypoth-
esis [8]. TReg cells become more abundant with age
in healthy subjects [80]. Whether the proliferation
of T cells in AD [80, 81] is effector or regulatory has
been the subject of controversy. Recently, Larbi et al.
re-analyzed their earlier postulation that TReg cells
may be upregulated in AD [82]. When a marker for
TRegs, FoxP3 [83], was considered, the authors
determined that the upregulation occurring was pro-
liferation of activated effector T cells [84], consistent
with our predictions for an HHAD.
One study found that TReg cells were increased in
mild cognitive impairment (MCI) and TReg-induced
immunosuppression was stronger in MCI than in
AD or controls [85]. This could be evidence that
among people with predisposition toward AD (i.e.
genetic or environmental risk factors), those with
adequate TReg function may merely develop MCI,
while those with inadequate TReg function may
develop AD. Also, it may be that during AD patho-
genesis, those with adequate TReg function may
Figure 4. Contemporary environment may be better indicator of Alzheimer’s burden than early-life environment
For each year (x), the regression coefficient (y) of the correlation between year’s (x) IMR and AD burden in 2004. IMR for the
various years were transformed by square root and natural log. See Supplementary Section S5. All correlations were significant
besides the years 1900, 1901 and 1911. Significance: 1902–19, P< 0.05; 1920–44, P< 0.01; 1945–2002, P< 0.000
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linger in the MCI phase for longer, while those with
inadequate TReg function may progress to AD more
rapidly.
It has already been well established that insuffi-
cient TReg numbers lead to excessive TH1 inflamma-
tion in autoimmunity and TH2 inflammation in atopy
[52, 86]. The inflammation characteristic of AD is
TH1 dominant [29, 87, 88]. In AD, amyloid-b
activates microglia and astrocytes, which stimulate
preferential TH1 proliferation [89], and AD patients
have elevated levels of TH1-associated cytokines
[90–92]. Non-steroidal anti-inflammatory drugs
have been demonstrated to be protective against
AD [93].
T cells may influence AD pathogenesis not only
from within the brain but also from the periphery.
Activated TH1 cells in the periphery could secrete
pro-inflammatory cytokines, which cross the blood–
brain barrier (BBB) and directly activate microglia
and astrocytes in the brain, as well as indirectly in-
duce inflammation by activating dendritic cells [89].
It should be investigated whether hygiene directly
affects the development of microglia. Microglia
sometimes exhibit a non-inflammatory phenotype,
in contrast to the pro-inflammatory phenotype
typical of the activated state in the context of
AD and other brain insults [5, 94], It is unknown
whether hygiene would promote development of
the inflammatory or non-inflammatory phenotypes
[5], and further research is needed to establish
the effect of microbial deprivation on microglial
development.
ApoE
ApoE-e4 is an allele that has pro-inflammatory
effects, and increases BBB permeability [95].
Compromise of the BBB would make other pro-
inflammatory mechanisms become exacerbated risk
factors for AD, when otherwise, inflammation might
have been limited to the periphery. There is already
evidence that ApoE alleles confer different degrees
of AD risk in different environments. While the e4 al-
lele was an AD risk factor among African Americans,
this was not the case among the Yoruba in Nigeria
[96], nor is e4 associated with increased risk among
Nyeri Kenyans, Tanzanians [97], Wadi Ara Arab
Israelis [98], Khoi San [99], Bantu and Nilotic
African cohorts [100]. These patterns support the
possibility that environmental factors such as micro-
bial diversity interact with inflammatory pathways to
influence AD risk.
Darwinian medicine
One of the major aims of Darwinian medicine is
understanding human health and disease within
the context of our species’ evolutionary history
[101]. In their formative 1991 paper, Williams and
Nesse discussed the promise for Darwinian medi-
cine to make strides in aging research [102]. There is
growing enthusiasm for Darwinian medicine
approaches to understanding aging [103], specific-
ally neurodegeneration [104] and more specifically
AD (Supplementary Section S7).
The hygiene hypothesis is an important contribu-
tion from Darwinian medicine [52]. Recently,
authors have suggested extending the hygiene hy-
pothesis toward explaining obesity [105] and certain
cancers [106, 107]. Thus far, the hygiene hypothesis
has been discussed mostly in the context of conse-
quences for early and mid-life pathologies, and
we feel that more attention should be paid to its
potential to explain patterns of disease in later life.
Study limitations
Some critics suggest that age-weighting is not re-
flective of social values [42, 108]. A systematic review
of GBD methodologies determined that the WHO’s
report [42] represented a rigorously comprehensive
methodology, but is still limited by the fact that many
developing countries use paper-based health sur-
veillance based more on estimates and projections
than actual counts. It is also possible that certain
predictive variables, especially urbanization, are
related to surveillance accuracy.
Large-scale epidemiological studies often suffer
from lack of surveillance and statistical limitations.
Much of public health and epidemiological research
is based on correlational studies, inherently
limited by the inability to demonstrate causality.
Nonetheless, these types of investigation provide
necessary perspective of environmental influences
on biological mechanisms, and help evaluate public
health burden and predict future healthcare needs.
Importance and applications
As AD becomes an increasingly global epidemic,
there is growing need to be able to predict AD rates
across world regions in order to prepare for the
future public health burden [39]. It is in low- and
middle-income countries that the sharpest rise is
predicted to occur in the coming decades [109].
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We suggest that ecological changes that will occur in
low- and middle-income countries as they become
more financially developed may affect AD rates in
ways not currently appreciated. Other authors have
also discussed the ways in which infectious disease
may affect patterns of non-communicable chronic
disease [110]. Disease predictions affect public
policy, healthcare prioritization, research funding
and resource allocation [111]. Better methods for
estimating AD rates could affect these policies and
strategies [112].
The next step in testing the HHAD should be
to directly investigate patients’ immune activity
throughout life and AD risk, preliminarily in a
cross-sectional study utilizing medical records,
serum analysis, or reliable interview techniques.
supplementary data
Supplementary data are available at EMPH online.
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